Sentences with phrase «of immunotherapy»

Several types of immunotherapy for glioblastoma are in late - stage clinical trials.

In a paper posted online by the journal Science, researchers at the Dana - Farber / Boston Children's Cancer and Blood Disorders Center report that, in mice with chronic viral infection, exhausted T cells are controlled by a fundamentally different set of molecular circuits than T cells effectively battling infections or cancer — a finding that suggests a way to increase the staying power of CAR T cells, a promising form of immunotherapy for cancer.

The Johns Hopkins team tested ImmunoMap's ability to correlate immune responses on receptor sequencing data from T - cells in the tumors of 34 patients with cancer enrolled in a nationwide clinical trial of the immunotherapy drug nivolumab.

STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells.

Due to this fact treatment of melanoma is mostly based in the development of immunotherapy for treatment of metastatic melanoma [3].

In 1953, she founded the Cancer Research Institute, which still exists today, to honor her father and advance the field of immunotherapy research.

To better leverage the benefits of immunotherapy in our patients, we're developing personalized approaches through vaccines and cellular therapies.

Tactiva's lead platform is a unique approach to adoptive cell transfer (ACT), a form of immunotherapy in which a patient's own immune cells are drawn from blood, genetically engineered, multiplied and injected back into the patient in order to launch a powerful attack against cancer.

Nivolumab belongs to a class of immunotherapy drugs called checkpoint inhibitors.

A fourth major avenue of immunotherapy for ovarian cancer is adoptive T cell transfer.

We offer a number of immunophenotyping kits to evaluate the efficacy of any immunotherapy against cancer (e.g., CD3 -, CD117 -, CD71 -, and CD25 - expressing cells) and to determine CD4 expression by T cells and macrophages in HIV - infected patients after highly active antiretroviral therapy (HAART).

As chair of the Cancer Research Institute's clinical trials network and director of immunotherapy clinical trials and monitoring at Memorial Sloan Kettering Cancer Center in New York, he is leading some of the most important clinical trials being conducted today.

Recent evidence suggests that one major roadblock for the effective use of immunotherapies in pancreatic cancer patients is that the tumors are effectively hidden, preventing the immune system from recognizing and killing them.

«We showed that there are markers on these stomach tumour cells that indicate they would be responsive to a type of immunotherapy called immune checkpoint inhibitors, in particular anti-PDL1 immunotherapy, which is already used with great success in the treatment of melanoma and certain other cancers.

The discovery could be utilized to improve the effectiveness of immunotherapy treatments in the fight against cancer.

The scientists say the findings reveal potential new drug targets and might aid efforts to extend the benefits of immunotherapy treatment to more patients and additional types of cancer.

, Dr. Jacqueline Shields, University of Cambridge, United Kingdom Speaker: Jacqueline Shields, University of Cambridge, United Kingdom Host: Postdoc Network DKFZ Outline of the talk The recent success of immunotherapy platforms to harness and reactivate the immune response represent a major therapeutic advancement, however, many patients still fail to respond or do not see lasting benefits.

Building on the pioneering work of the Ludwig Cancer Research (LICR), iTeos is aiming to unlock the full potential of immunotherapy by improving the frequency, depth and duration of response, and by extending therapeutic benefit to more patients.

The approach offers a way to widen the use of a new generation of immunotherapy drugs from the likes of Merck & Co (MRK.N), Bristol - Myers Squibb (BMY.N) and Roche (ROG.S) that currently only work for a limited number of patients.

The recent success of immunotherapy platforms to harness and reactivate the immune response represent a major therapeutic advancement, however, many patients still fail to respond or do not see lasting benefits.

That's why some of the currently approved courses of immunotherapy span only a few doses over a relatively short period: The idea is that as soon as the body learns, it remembers.

«Gradual release of immunotherapy at site of tumor surgery prevents tumors from returning.»

It may be necessary to reduce a dogs sensitivity to specific allergens which is the treatment goal of immunotherapy.

To further advance the study of immunotherapy for glioblastoma, the Parker Institute for Cancer Immunotherapy is organizing a workshop starting July 27 in Los Angeles.

The April issue of Scientific American highlights these emerging therapies, but we have covered the growing promise of immunotherapy for quite a while.

In addition to CAR - T cell therapy, we focus on other types of immunotherapy research, such as vaccine therapy and checkpoint inhibitors.

«The potential benefit of immunotherapy far outweighs the worry by miles at this time, so nobody should give up that option.»

One of the goals of our kidney cancer team is to lead the development of immunotherapy as a prominent treatment for kidney cancer.

The two investigators address such issues in their leadership roles of the immunotherapy platform for MD Anderson's Moon Shots Program.

While checkpoint inhibitors got most of the attention at ASCO, there were also several exciting presentations on other areas of immunotherapy.

CRI: What's the advantage of immunotherapy over other cancer therapies?

Journal of Immunotherapy 2010 Oct. 33 (8), 759 - 768 (PMID: 20842061)

City of Hope continues to be at the forefront of a powerful form of immunotherapy known as chimeric antigen receptor (CAR) T cell therapy.

These types of drugs could potentially be used with other sorts of immunotherapies, which are all the rage in biopharma these days.

At Mayo, some immunologists work on basic research and others lean more toward the clinical applications of immunotherapy.

With the soaring costs of some new drug treatments do you worry that most of these immunotherapies will be beyond the financial reach of all but the very rich?

Commenting on the research, Prof Rolf Stahel, Professor of oncology at the University Hospital Zurich in Zurich, Switzerland, said: «The findings suggest that the addition of this type of immunotherapy improves the response rate, and provides a longer progression free survival, compared to what would be expected with chemotherapy alone.

Allison, chair of the immunology department at the University of Texas M.D. Anderson Cancer Center in Houston and executive director of its research center on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunotherapy.

The session continued with talks from Sabrina Schindler (SWISS1, Zurich) who is working on profiling immune responses in patients undergoing immunotherapy, and Sonia Leonardelli (ESR14, Essen) who presented data on chromosomal abnormaities predisposing to the development of immunotherapy resistance.

June 13, 2016 Radiation and vaccination can magnify effects of immunotherapy By combining local radiation therapy and anti-cancer vaccines with checkpoint inhibitors, researchers from the University of Chicago, working with mice, were able to increase the response rate for these new immunotherapy agents.

For metastatic melanoma, there are currently three different types of immunotherapy approved for use, and we specifically looked at that population of people.»

A range of immunotherapies are currently in use, yet their efficacy can be varied and differ from patient to patient.

An alternative would be to go through a series of immunotherapy shots.